Gut bacteria boost? new trial combines probiotic with cancer therapy for rectal tumors
NCT ID NCT07458529
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether adding a probiotic called Probio-M9 to standard chemoradiation and an immunotherapy drug (tislelizumab) can improve outcomes for people with locally advanced rectal cancer. About 50 participants will be randomly assigned to receive either the probiotic or a placebo alongside their cancer treatment before surgery. The main goal is to see if the probiotic helps more tumors completely disappear after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Probio-M9 (a probiotic) and tislelizumab (an immunotherapy drug)
- What this could lead to
- If it works, this could lead to a more effective pre-surgery treatment for certain rectal cancers, potentially increasing the chance of complete tumor disappearance.
- What could go wrong
- This is a small, early-phase trial (50 people) at a single center. The probiotic may not add benefit, and immunotherapy can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seventh Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100700, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can an AI coach and simple exercises help cancer patients fight frailty?
- Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?
- Triple therapy takes on rare, aggressive kidney cancer
- Bladder cancer drug delivered directly: a new hope for BCG failures
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?